Ferretti; Antonio Christian

Patent Applications and Registrations

Patent applications and USPTO patent grants for Ferretti; Antonio Christian.The latest application filed is for "process for the preparation of bromodomain inhibitor".

Company Profile

3.6.8

Ferretti; Antonio Christian - Summit NJ

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Process For The Preparation Of Bromodomain Inhibitor App 20220064121 - TRAVERSE; John Fitzgerald ; et al.	2022-03-03
Solid forms of 2-(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyri- midine-5-carboxamide, compositions thereof and methods of their use Grant 10,517,873 - Beauchamps , et al. Dec	2019-12-31
Solid Forms Of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyri- Midine-5-carboxamide, Compositions The App 20190167678 - Beauchamps; Marie Georges ; et al.	2019-06-06
Forms and compositions of an ERK inhibitor Grant 10,202,364 - Ferretti , et al. Feb	2019-02-12
Forms And Compositions Of An Erk Inhibitor App 20180362498 - Ferretti; Antonio Christian ; et al.	2018-12-20
Forms and compositions of an ERK inhibitor Grant 10,005,760 - Ferretti , et al. June 26, 2	2018-06-26
Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-- 3,4-dihydropyrazino[2,3- B]pyrazin-2(1H)-one, a solid form there of and methods of their use Grant 9,974,786 - Beauchamps , et al. May 22, 2	2018-05-22
Pharmaceutical Compositions Of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-- 3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, A Solid Form Thereof And Methods Of Their Use App 20180071287 - BEAUCHAMPS; Marie Georges ; et al.	2018-03-15
Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-- 3,4-dihydropyrazino [2,3-B]pyrazin-2(1H)-one, a solid form thereof and methods of their use Grant 9,795,603 - Beauchamps , et al. October 24, 2	2017-10-24
Forms And Compositions Of An Erk Inhibitor App 20170226083 - Ferretti; Antonio Christian ; et al.	2017-08-10
Pharmaceutical Compositions Of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-- 3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, A Solid Form Thereof And Methods Of Their Use App 20170182042 - BEAUCHAMPS; Marie Georges ; et al.	2017-06-29
Pharmaceutical compositions of 7-(6-(2-hydroxypropan-2-YL)pyridin-3-YL)-1-((trans)-4-methoxycyclohexyl)-- 3,4-dihydropyrazino [2,3-B]pyrazin-2(1H)-one, a solid form thereof and methods of their use Grant 9,604,939 - Beauchamps , et al. March 28, 2	2017-03-28
Solid Forms Of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyri- Midine-5-carboxamide, Compositions Thereof And Methods Of Their Use App 20150210650 - Ferretti; Antonio Christian ; et al.	2015-07-30
Pharmaceutical Compositions Of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-- 3,4-dihydropyrazino [2,3-b]pyrazin-2(1h)-one, A Solid Form Thereof And Methods Of Their Use App 20140356430 - BEAUCHAMPS; Marie Georges ; et al.	2014-12-04

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.